Rankings
▼
Calendar
ABCL Q4 2025 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena
ABCL
AbCellera Biologics Inc.
$1B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$45M
+788.2% YoY
Gross Profit
$45M
100.0% margin
Operating Income
-$29M
-63.7% margin
Net Income
-$9M
-19.9% margin
EPS (Diluted)
$-0.03
QoQ Revenue Growth
+400.9%
Cash Flow
Operating Cash Flow
-$35M
Free Cash Flow
-$45M
Stock-Based Comp.
$13M
Balance Sheet
Total Assets
$1.4B
Total Liabilities
$216M
Stockholders' Equity
$1.1B
Cash & Equivalents
$155M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$45M
$5M
+788.2%
Gross Profit
$45M
$5M
+788.2%
Operating Income
-$29M
-$73M
+60.7%
Net Income
-$9M
-$34M
+73.9%
Revenue Segments
License
$36M
82%
Research Fees
$8M
18%
← FY 2025
All Quarters